Clinical trials: First Line Treatment
Head and Neck Cancer
Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in…
- Trial name
- NCT05287113
- Testing
- Retifanlimab, INCAGN02385, INCAGN02390
- Where
- 91 sites in United States, Belgium and 12 more
- Volunteers
- 176 people
- Sponsor
- Incyte Biosciences International Sàrl
Renal Cell Cancer
A Study of Avastin (Bevacizumab) in Combination With Standard Therapy in Patients With Metastatic Renal Cell Cancer.
This single arm study will assess the efficacy and safety of Avastin in combination with interferon alfa-2a and vinblastine as first line treatment in patients with metastatic renal cell cancer.
- Trial name
- NCT00520403
- Testing
- bevacizumab [Avastin], Interferon alfa-2a, Vinblastine
- Where
- 16 sites in Germany
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Metastatic Colorectal Cancer
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
This is a Phase 1b/2a study investigating the safety and efficacy of Sym004, an investigational medicinal product (IMP), in combination with FOLFIRI (chemotherapy) when administered every second week (Q2W).
- Trial name
- NCT02568046
- Testing
- Sym004, FOLFIRI
- Where
- 8 sites in United States, Spain
- Volunteers
- 10 people
- Sponsor
- Symphogen A/S
Cutaneous Squamous Cell Carcinoma
Treatment With Nab-paclitaxel in Cutaneous SCC
This is an investigator initiated phase II study to assess the efficacy of a chemotherapy called nab-paclitaxel as first line cytotoxic chemotherapy in subjects with unresectable locally advanced or metastatic cutaneous squamous…
- Trial name
- NCT02076243
- Testing
- nab-paclitaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Head and Neck Squamous Cell Carcinoma (HNSCC)
Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
The purpose of this study is to assess the efficacy and safety of intratumoral (IT) ulevostinag PLUS pembrolizumab (MK-3475) compared to pembrolizumab alone as a first line treatment of adults with metastatic or unresectable…
- Trial name
- NCT04220866
- Testing
- Ulevostinag, Pembrolizumab
- Where
- 34 sites in United States, Australia and 8 more
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
7-hydroxystaurosporine and Topotecan Hydrochloride in Treating Patients With Relapsed or Progressed Small Cell Lung Cancer
This phase II trial is studying how well giving UCN-01 together with topotecan works in treating patients with small cell lung cancer that relapsed or progressed after previous chemotherapy.
- Trial name
- NCT00098956
- Testing
- topotecan hydrochloride, 7-hydroxystaurosporine
- Where
- Canada
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Squamous Cell, Non-small-cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976362
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma
A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma
The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free…
- Trial name
- Cassiopeia (NCT02541383)
- Testing
- Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD), Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab, Daratumumab
- Where
- 107 sites in Belgium, France and 1 more
- Volunteers
- 1,085 people
- Sponsor
- Intergroupe Francophone du Myelome
Carcinoma, Renal Cell
Sorafenib Dose Escalation in Renal Cell Carcinoma
Sorafenib is a new drug, which is approved under the brand name Nexavar for the treatment of advanced kidney cancer. It is also currently being tested in various other cancers.
- Trial name
- NCT00618982
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 22 sites in France, Germany and 3 more
- Volunteers
- 83 people
- Sponsor
- Bayer
Non-Small-Cell Lung Carcinoma
Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
The primary purpose of this clinical research study is to learn if patients treated with the combination of Taxane/Carboplatin plus Cetuximab (C/T/C) have a longer progression-free survival than patients treated with…
- Trial name
- NCT00112294
- Testing
- Paclitaxel (Taxane), Docetaxel (Taxane), Carboplatin
- Where
- 124 sites in United States
- Volunteers
- 755 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung
Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)
Phase 1b/Phase 2 Umbrella Study; open-label, multi-center, parallel group study. Sasanlimab (a PD-1 antagonist monoclonal antibody) will be combined with a different targeted therapy in each sub-study.
- Trial name
- NCT04585815
- Testing
- Sasanlimab Prefilled syringe, Encorafenib, Binimetinib
- Where
- 55 sites in United States, Australia and 2 more
- Volunteers
- 34 people
- Sponsor
- Pfizer
Colorectal Cancer
A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
This 2 arm study will assess the efficacy and safety of intermittent oral Xeloda, or iv fluorouracil/leucovorin, in combination with intravenous Eloxatin (oxaliplatin) in patients previously treated for metastatic colorectal…
- Trial name
- NCT00069108
- Testing
- 5 FU, Leucovorin, Oxaliplatin
- Where
- 87 sites in United States, Belgium and 18 more
- Volunteers
- 627 people
- Sponsor
- Hoffmann-La Roche
Relapsing Remitting Multiple Sclerosis
Evaluation of Patient Retention of Fingolimod vs. Currently Approved Disease Modifying Therapy in Patients With Relapsing Remitting Multiple Sclerosis.
A 12 month study where 852 patients with relapsing remitting MS will be randomized 1:1 to fingolimod or approved disease modifying therapy.
- Trial name
- PREFERMS (NCT01623596)
- Testing
- Fingolimod, Disease Modifying therapy
- Where
- 123 sites in United States, Puerto Rico
- Volunteers
- 881 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasms
A Study Of Palbociclib (PD-0332991) + Letrozole VS. Placebo+ Letrozole For 1st Line Treatment Of Asian Postmenopausal Women With ER+/HER2- Advanced Breast Cancer [PALOMA-4]
The study is designed to compare the clinical benefit following treatment with letrozole in combination with Palbociclib versus letrozole in combination with placebo in Asian postmenopausal women with ER(+)/HER2(-) advanced…
- Trial name
- NCT02297438
- Testing
- Palbociclib, Letrozole
- Where
- 54 sites in China, Hong Kong and 3 more
- Volunteers
- 340 people
- Sponsor
- Pfizer
Multiple Myeloma
Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy
In this study, investigators will evaluate the activity of bendamustine, bortezomib and dexamethasone (BBD). This regimen combines 3 agents with high activity in multiple myeloma, with different mechanisms of action and…
- Trial name
- NCT01056276
- Testing
- Bendamustine, Bortezomib, Dexamethasone
- Where
- 13 sites in United States
- Volunteers
- 59 people
- Sponsor
- SCRI Development Innovations, LLC
Gastric Cancer
Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients
To assess the efficacy of olaparib when given in combination with paclitaxel compared with paclitaxel alone as defined by progression-free survival (PFS), in all patients with recurrent and metastatic gastric cancer who progress…
- Trial name
- NCT01063517
- Testing
- olaparib, paclitaxel
- Where
- 7 sites in South Korea
- Volunteers
- 124 people
- Sponsor
- AstraZeneca
Fungal Infection
Posaconazole Treatment of Invasive Fungal Infection (IFI) (P05551)
The purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with Posaconazole Oral Suspension in participants with IFI
- Trial name
- NCT00811642
- Testing
- Posaconazole
- Volunteers
- 63 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer
This study is designed to study the role of an active and well-tolerated non-platinum agent, gemcitabine, in a combination regimen with pemetrexed in the first-line treatment of advanced NSCLC.
- Trial name
- NCT00193414
- Testing
- Pemetrexed, Gemcitabine
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer
This was a multi-center, multinational, randomized, open-label, Phase III study comparing combination taxane-based chemotherapy plus lapatinib to combination taxane-based chemotherapy plus trastuzumab in women with documented…
- Trial name
- NCT00667251
- Testing
- trastuzumab, docetaxel, lapatinib ditosylate
- Where
- 257 sites in United States, Argentina and 19 more
- Volunteers
- 652 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Pulmonary
A Study of First-Line Ambrisentan and Tadalafil Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to compare the two treatment strategies; first-line combination therapy (ambrisentan and tadalafil) versus first-line monotherapy (ambrisentan or tadalafil) in subjects with Pulmonary Arterial…
- Trial name
- AMBITION (NCT01178073)
- Testing
- ambrisentan, tadalafil
- Where
- 143 sites in United States, Australia and 12 more
- Volunteers
- 610 people
- Sponsor
- GlaxoSmithKline